KemPharm downgraded by HC Wainwright & Co. with a new price target
$KMPH
Biotechnology: Pharmaceutical Preparations
Health Care
HC Wainwright & Co. downgraded KemPharm from Buy to Neutral and set a new price target of $12.00 from $24.00 previously
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/17/2022 | $20.00 | Overweight | Cantor Fitzgerald |
| 9/15/2022 | $20.00 | Buy | Canaccord Genuity |
| 1/31/2022 | $10.00 → $11.00 | Neutral → Buy | HC Wainwright & Co. |